Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCRαβ+/CD19+ Depleted HSCT for Malignant and Non-malignant Disorders
NCT04088760Phase 2Terminated
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2019
- Primary completion
- May 2021
- Countries
- 1
01
Overview
A Phase 2 trial of T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells in hematologic malignancy, hematologic disorder, sponsored by Cincinnati Children's Hospital Medical Center. Started Sep 2019; status: terminated.
02
Drugs
T-cell receptor alpha/beta and CD19 depleted hematopoietic stem cells
03
Conditions
hematologic malignancyhematologic disorder
Beyond the preview
Go deeper on NCT04088760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088760.